Business
Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis
Management and Leading KOLs will Provide Detailed Review of Completed FX-322 Clinical Data in Subjects with Sensorineural Hearing Loss (SNHL), Supporting
About this update from Korro Bio, Inc.
[{"type":"text","content":"\nManagement and Leading KOLs will Provide Detailed Review of Completed FX-322 Clinical Data in Subjects with Sensorineural Hearing Loss (SNHL), Supporting Design of FX-322-208 Phase 2b Study\n\nNew Hearing Restoration Program Advances Toward Clinical Studies Providing Broader Cochlear Exposure with the Potential to Address Expanded SNHL Patient Populations\n\nNovel Remyelinating Agent Against a New Biological Target Being Advanced for Multiple Sclerosis (MS); In Vivo Data Show Substantially Greater Activity than Biologic or Small Molecule Comparators\n\n LEXINGTON, Mass.--(BUSINESS WIRE)--\nFrequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today will host a virtual R&D event. The webcast can be accessed here.\n\n“We look forward to highlighting the extensive data supporting our Phase 2b study (FX-322-208) in patients with sensorineural hearing loss (SNHL), where we have seen clear clinical improvements in speech perception in patient groups that include millions of individuals in the US alone. We have alignment with the FDA on speech perception as the primary efficacy endpoint and will detail the importance of this measure for patients. Our Phase 2b study is enrolling subjects who we believe fit squarely in the range where we have seen clinically meaningful hearing improvements, and we will detail the design of this study,” said David L. Lucchino, Frequency’s Chief Executive Officer.\n\nMr. Lucchino continued: “We will also unveil two new research programs that demonstrate the potential of our progenitor cell activation (PCA) approach. First, we will introduce FX-345, a new hearing restoration candidate designed for greater distribution through the cochlea, potentially enabling the treatment of expanded SNHL patient populations. We also have a highly promising novel therapeutic approach for multiple sclerosis, remyelinating agents that demonstrate a level of activity that far exceeds alternatives that have been developed to date.”\n\nEvent Highlights:\n\nFX-322\n\n\nClinical data review from four completed FX-322 clinical studies, including 169 subjects with a range of hearing loss severities and SNHL etiologies (sudden, noise-induced, age-related).\n\n\nAnalysis of statistically...